Scalper1 News
Biotech Regeneron Pharmaceuticals is shaping up to have an eventful year. Regeneron (REGN) has already become a leading stock thanks to the successful launch of Eylea, its treatment for wet age-related macular degeneration, a type of vision loss. It touched a record high Monday. By August, the product is also expected to be approved for diabetic macular edema. Attention, however, is now shifting to the other drugs in the company’s pipeline. Wall Scalper1 News
Scalper1 News